Abstract
MicroRNAs (miRNAs) are de-regulated in cancer versus the normal tissue counterpart and actively participate in human carcinogenesis. Among the genes whose expression is under their control there are both oncogenes and tumor suppressor genes, revealing that it is not only limiting but simply wrong to assign them a function just as oncogenes or as tumor suppressor genes. In addition to primary tumors, miRNAs can be detected in almost all human body fluids and effectively help to diagnose cancer and to prognosticate clinical outcome and response to treatment of tumors. The advent of miRNA mimic and miRNA silencing molecules has allowed to modulate miRNA expression in tumors, showing that miRNAs can be effectively used as therapeutic agents. This review will focus on those findings that have provided the rationale for the use of miRNAs as patient “tailored” anti-cancer agents.
Keywords: Biomarker, cancer, drug resistance, microRNA, oncogene, therapy, tumor suppressor gene.
Current Molecular Medicine
Title:MicroRNAs and Cancer: Towards a Personalized Medicine
Volume: 13 Issue: 5
Author(s): M. Fabbri
Affiliation:
Keywords: Biomarker, cancer, drug resistance, microRNA, oncogene, therapy, tumor suppressor gene.
Abstract: MicroRNAs (miRNAs) are de-regulated in cancer versus the normal tissue counterpart and actively participate in human carcinogenesis. Among the genes whose expression is under their control there are both oncogenes and tumor suppressor genes, revealing that it is not only limiting but simply wrong to assign them a function just as oncogenes or as tumor suppressor genes. In addition to primary tumors, miRNAs can be detected in almost all human body fluids and effectively help to diagnose cancer and to prognosticate clinical outcome and response to treatment of tumors. The advent of miRNA mimic and miRNA silencing molecules has allowed to modulate miRNA expression in tumors, showing that miRNAs can be effectively used as therapeutic agents. This review will focus on those findings that have provided the rationale for the use of miRNAs as patient “tailored” anti-cancer agents.
Export Options
About this article
Cite this article as:
Fabbri M., MicroRNAs and Cancer: Towards a Personalized Medicine, Current Molecular Medicine 2013; 13 (5) . https://dx.doi.org/10.2174/1566524011313050006
DOI https://dx.doi.org/10.2174/1566524011313050006 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Increased Paternal Age and Child Health and Development
Current Pediatric Reviews HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Styrene Maleic Acid Neocarzinostatin Treatment for Hepatocellular Carcinoma
Current Medicinal Chemistry - Anti-Cancer Agents Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome
Current Diabetes Reviews Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks
Current Medicinal Chemistry Therapy of Hepatocellular Carcinoma with Rhenium-188 Lipiodol
Current Radiopharmaceuticals Recent Insights into COVID-19 in Children and Clinical Recommendations
Current Pediatric Reviews Secreted Heat Shock Protein-90α: A More Effective and Safer Target for Anti-Cancer Drugs?
Current Signal Transduction Therapy Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Role of Mechanoinsensitive Nociceptors in Painful Diabetic Peripheral Neuropathy
Current Diabetes Reviews Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology